IN BRIEF: Positive results from Open Orphan human challenge study

Open Orphan PLC - pharmaceutical services provider - Sees positive results from a human challenge ...

Alliance News 17 February, 2022 | 8:13PM
Email Form Facebook Twitter LinkedIn RSS

Open Orphan PLC - pharmaceutical services provider - Sees positive results from a human challenge study assessing its respiratory syncytial virus antiviral candidate, EDP-938. Says results from the study have been published in The New England Journal of Medicine. hVIVO, a subsidiary of Open Orphan, conducted the Phase 2a, double-blind, placebo-controlled trial.

Andrew Catchpole, chief scientific officer of hVIVO, says: "It's pleasing to see another of our clients getting such positive results from a human challenge study that we conducted, and that the data has been published in The New England Journal of Medicine. EDP-938 is a potentially important medicine that could help reduce the global impact of RSV, and I look forward to following Enanta's continued progression of the candidate through further clinical trials."

Current stock price: 16.00 pence

12m-month change: down 42%

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Open Orphan PLC 14.76 GBX 9.33 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.